OMT/mTBI: The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine

Sponsor
University of California, San Diego (Other)
Overall Status
Completed
CT.gov ID
NCT03588364
Collaborator
(none)
11
1
2
32.5
0.3

Study Details

Study Description

Brief Summary

This study evaluates the use of osteopathic manipulation (manual medicine) for migraine headache following traumatic head injury. Headache is an important and very common somatic complaint among people with traumatic brain injury and an important cause of disability in the United States. Over 15-percent of soldiers deployed to Iraq sustained concussion. A majority of these patients suffer from headaches. Many of these are classified as migraine headache that do not respond to medications. Osteopathic manipulation is practiced by physicians in the United States and has been shown to be beneficial in some migraine patients. However, its use in the management of persistent post-traumatic headaches has not been explored. The investigators will use a randomized cross-over design to evaluate post-traumatic migraine patients' response to osteopathic manipulation.

Condition or Disease Intervention/Treatment Phase
  • Other: Osteopathic Manipulation
N/A

Detailed Description

This is a 30-week prospective, randomized delayed treatment control group design in which 20 participants from the community will be randomized 1:1 into (a) an immediate treatment group that will receive 12 weeks of osteopathic manipulation (OMT) treatment plus standard of care right away or (b) delayed treatment group that will receive 12 weeks of OMT plus standard of care after a 6-week waiting period. The delayed treatment group initially serves as a control condition but then receives the experimental treatment. The investigators selected this control condition to improve our statistical power in this small pilot study. As noted, all participants will continue to receive standard of care throughout the study as a washout is not feasible with osteopathic manipulation and removing standard of care could exacerbate the participant's symptoms. Participants in both arms will be followed for another 12 weeks after the 12 weeks of OMT, resulting in 24 weeks of study participation for the immediate treatment group and 30 weeks of study participation for the delayed treatment group, with participants in both arms answering a series of questionnaires to evaluate migraine frequency and impact, treatment efficacy, side effects, adherence t standard of care and depressive symptoms every 6 weeks throughout their study participation. Participant encounters will consist of screening, psychometric and functional scale administration at every 6 weeks for a total of 24-30 weeks, as well as 12 weeks of OMT treatments for participants in both study arms. Study participants will likely come from UCSD internal referrals.

Study Design

Study Type:
Interventional
Actual Enrollment :
11 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
This is a 30-week prospective, randomized delayed treatment control group design in which 20 participants from the community will be randomized 1:1 into (a) an immediate treatment group that will receive 12 weeks of osteopathic manipulation (OMT) treatment plus standard of care right away or (b) delayed treatment group that will receive 12 weeks of OMT plus standard of care after a 6-week waiting period. The delayed treatment group initially serves as a control condition but then receives the experimental treatment.This is a 30-week prospective, randomized delayed treatment control group design in which 20 participants from the community will be randomized 1:1 into (a) an immediate treatment group that will receive 12 weeks of osteopathic manipulation (OMT) treatment plus standard of care right away or (b) delayed treatment group that will receive 12 weeks of OMT plus standard of care after a 6-week waiting period. The delayed treatment group initially serves as a control condition but then receives the experimental treatment.
Masking:
Triple (Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Only the study coordinator and the participants are privy to the assigned treatment arm (immediate vs. delayed) until the study is complete and the database is locked.
Primary Purpose:
Treatment
Official Title:
The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine
Actual Study Start Date :
Sep 15, 2016
Actual Primary Completion Date :
Dec 1, 2018
Actual Study Completion Date :
Jun 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Osteopathic Manipulation

Twelve weekly sessions using the techniques of osteopathy in the cranial field.

Other: Osteopathic Manipulation
Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.

No Intervention: Waitlist Control

Six-week waiting period.

Outcome Measures

Primary Outcome Measures

  1. Headache Frequency Log [6 weeks]

    Participants will complete a form indicating the frequency, location, duration, characteristics, and associated features of their headache.

Secondary Outcome Measures

  1. Migraine Disability Assessment Score (MIDAS) [6 weeks]

    Scale measures migraine disability by asking participants to indicate number of various events missed (or completed with reduced productivity) over the past three months; as well as average pain associated with headaches in the past 3 months.

  2. Center for Epidemiological Studies-Depression (CES-D) [6 weeks]

    20-item measure that asks respondents to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms.

  3. 36-Item Short Form Survey Instrument (MOS-SF-36) [6 weeks]

    36-item, patient-reported survey of health-related quality of life. Each of the eight scales is transformed into a 0-100 scale. The 8 scales include: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • History of TBI, concussion, post-concussive syndrome

  • Headache frequency >/equal 4 per month

  • Post-traumatic headache, migraine type

  • MIDAS Grade I-IV

  • Headaches continue to occur 3 months to 1 year after the injury

  • No history of uncontrolled migraine prior to head injury

Exclusion Criteria:
  • Headache medication change (Tricyclic antidepressant, antiepileptic medication, propranolol, verapamil, duloxetine, butterbur, Botox) within 30 days

  • Non-pharmacologic headache management change (reduction in caffeine intake, reduction in alcohol intake, sleep hygiene, exercise) within 30 days

  • Less than 3 months from injury

  • History of uncontrolled migraine prior to TBI

  • Currently taking oral anti-coagulants

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of California, San Diego La Jolla California United States 92093

Sponsors and Collaborators

  • University of California, San Diego

Investigators

  • Principal Investigator: Hollis H King, DO, PhD, University of California, San Diego

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hollis King, Health Sciences Clinical Professor, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT03588364
Other Study ID Numbers:
  • OMT/mTBI
First Posted:
Jul 17, 2018
Last Update Posted:
Jun 12, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hollis King, Health Sciences Clinical Professor, University of California, San Diego
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 12, 2019